ALPHE.PA
Price:
$2
Market Cap:
$15.83M
Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.
Industry
Biotechnology
IPO Date
2021-02-05
Stock Exchange
EURONEXT
Ticker
ALPHE.PA
According to Pherecydes Pharma SA’s latest financial reports and current stock price. The company's current PE Ratio is -2.67. This represents a change of -Infinity% compared to the average of 0 of the last 4 quarters.
The mean historical PE Ratio of Pherecydes Pharma SA over the last ten years is -20.73. The current -2.67 PE Ratio has changed 1.19% with respect to the historical average. Over the past ten years (40 quarters), ALPHE.PA's PE Ratio was at its highest in in the December 2019 quarter at 0. The PE Ratio was at its lowest in in the December 2019 quarter at 0.
Average
-20.73
Median
-20.44
Minimum
-35.80
Maximum
-2.80
Discovering the peaks and valleys of Pherecydes Pharma SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 45.37%
Maximum Annual PE Ratio = -2.80
Minimum Annual Increase = -76.47%
Minimum Annual PE Ratio = -35.80
Year | PE Ratio | Change |
---|---|---|
2022 | -2.80 | -76.47% |
2021 | -11.92 | -34.50% |
2020 | -18.19 | -44.81% |
2019 | -32.97 | 45.37% |
2018 | -22.68 | -36.65% |
The current PE Ratio of Pherecydes Pharma SA (ALPHE.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.97
5-year avg
-17.71
10-year avg
-20.73
Pherecydes Pharma SA’s PE Ratio is less than Medesis Pharma S.A. (-0.92), greater than Hydrogen-Refueling-Solutions SA (-5.21), less than OSE Immunotherapeutics SA (3.45), less than ERYTECH Pharma S.A. (-0.11), greater than MedinCell S.A. (-14.49),
Company | PE Ratio | Market cap |
---|---|---|
-0.92 | $1.80M | |
-5.21 | $54.56M | |
3.45 | $133.17M | |
-0.11 | $48.66M | |
-14.49 | $517.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pherecydes Pharma SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Pherecydes Pharma SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Pherecydes Pharma SA's PE Ratio?
How is the PE Ratio calculated for Pherecydes Pharma SA (ALPHE.PA)?
What is the highest PE Ratio for Pherecydes Pharma SA (ALPHE.PA)?
What is the 3-year average PE Ratio for Pherecydes Pharma SA (ALPHE.PA)?
What is the 5-year average PE Ratio for Pherecydes Pharma SA (ALPHE.PA)?
How does the current PE Ratio for Pherecydes Pharma SA (ALPHE.PA) compare to its historical average?